Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish | The Motley Fool
This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment.

Source: The Motley Fool
This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment.